Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380120 | PMC |
| http://dx.doi.org/10.1177/20499361241272510 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematic Review on Chemsex: Advocating for Inclusive Research and Primary Prevention.
J Prev (2022)
January 2025
Faculty of Health Sciences, Valencian International University, Pintor Sorolla 21, 46002, Valencia, Spain.
Chemsex is a specific practice of sexualized drug use (SDU), linked mainly to the group of men who have sex with men (MSM). This practice has become a public health problem due to the increase in sexually transmitted infections and HIV. However, there are groups and aspects that require greater visibility and research.
View Article and Find Full Text PDFCurrent Status of Neoadjuvant Treatment Before Surgery in High-Risk Localized Prostate Cancer.
Cancers (Basel)
December 2024
Urology Department, Hospital Clínico San Carlos, 28040 Madrid, Spain.
Localized high-risk (HR) prostate cancer (PCa) is a heterogeneous disease whose likelihood of a biochemical recurrence, metastatic progression and cancer-related mortality after initial treatment is higher when compared with patients with low (LR) or intermediate-risk (IR) disease. In the past, neoadjuvant therapy has shown an improvement in postoperative oncological variables but failed to demonstrate any survival advantages. With the promising results from novel treatments in metastatic and non-metastatic castration resistant PCa settings, new evidence has appeared in the literature in the neoadjuvant setting.
View Article and Find Full Text PDFThe Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine-Including Biomarker Analyses.
Cancers (Basel)
December 2024
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita 5650871, Japan.
Background: FOLFIRI (5-FU + leucovorin + irinotecan) plus ramucirumab is one of the standards in second-line metastatic colorectal cancer (CRC) patients progressing after treatment with oxaliplatin/fluoropyrimidine with bevacizumab, but there is no evidence on its efficacy without prior bevacizumab. Moreover, VEGF-D has not been confirmed as a predictive biomarker for ramucirumab's efficacy, either.
Methods: The RAINCLOUD study was a multicenter, single-arm, phase II trial conducted in Japan.
Elucidation of Factors Affecting the Age-Dependent Cancer Occurrence Rates.
Int J Mol Sci
December 2024
Systems Biology Laboratory for Metabolic Reprogramming, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Cancer occurrence rates exhibit diverse age-related patterns, and understanding them may shed new and important light on the drivers of cancer evolution. This study systematically analyzes the age-dependent occurrence rates of 23 carcinoma types, focusing on their age-dependent distribution patterns, the determinants of peak occurrence ages, and the significant difference between the two genders. According to the SEER reports, these cancer types have two types of age-dependent occurrence rate (ADOR) distributions, with most having a unimodal distribution and a few having a bimodal distribution.
View Article and Find Full Text PDFPhysico-Chemical Properties of Granular Sorbents Based on Natural Bentonite Modified by Polyhydroxocations of Aluminum and Iron (III) by Co-Precipitation.
Molecules
January 2025
Department of General and Biological Chemistry, Astana Medical University, 010000 Astana, Kazakhstan.
The physicochemical and adsorption properties of granular sorbents based on natural bentonite and modified sorbents based on it have been studied. It was found that modification of natural bentonite with iron (III) polyhydroxocations (mod. 1_Fe_5 GA) and aluminum (III) (mod.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!